NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal third quarter revenues decreased 24 percent year over year and fell short of the consensus Wall Street estimate.
For the three months ended March 31, the firm reported total revenues of $164 million compared to $216.6 million in its fiscal Q3 2019. The consensus Wall Street estimate for the quarter was $167.2 million.